603108 润达医疗
2026/09 - 九个月
人民幣(K¥)
与去年同期
比较
2025/12
人民幣(K¥)
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
营业总收入4,791,534-9.05%6,998,5308,311,7809,147,37310,494,419
减:营业总成本4,751,236-10.48%7,099,4747,994,7838,651,9939,643,284
    其中:营业成本3,669,915-11.24%5,501,6286,203,4926,718,3717,557,067
               财务费用201,674-0.73%273,516313,435316,682323,591
               资产减值损失(777)1,004.60%(208,737)(36,170)(34,500)(40,772)
公允价值变动收益------------
投资收益24,069-64.01%20,795109,821231,999137,048
    其中:对联营企业和合营企业的投资收益24,048-63.53%18,978108,488139,609138,057
营业利润(33,514)-41.72%(450,256)354,060646,803816,373
利润总额(55,187)-10.68%(460,637)345,542655,555819,651
减:所得税费用92,40843.46%57,514156,084212,920164,541
净利润(147,595)16.95%(518,151)189,458442,636655,110
减:非控股权益25,663-29.67%30,243134,177169,339237,364
股东净利润(173,258)6.49%(548,394)55,281273,296417,746

市场价值指针
每股收益 (元) *-0.2907.41%-0.9100.0900.4700.720
每股派息 (元) *------0.0300.1000.150
每股净资产 (元) *5.962-12.81%6.1947.1367.0606.519
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容